/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK)
Telix Pharmaceuticals is experiencing a re-acceleration in revenue growth, reaching 16.6% in 2026Q2, as its radiopharmaceutical portfolio gains commercial traction.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | $0.11+140.3% vs $0.04 | $477M-0.5% vs $480M |
Q1 2026 Feb 19, 2026 | -$0.01-135.4% vs $0.03 | $413M-1.2% vs $418M |
Q3 2025 Aug 20, 2025 | -$0.01-105.1% vs $0.13 | $390M-0.0% vs $390M |
Q1 2025 Feb 20, 2025 | $0.11+22.5% vs $0.09 | $267M+97.9% vs $135M |
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK)
Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or higher New Cook Medical agreement positions TULSA-PRO ® within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach across the United States Richard Fabian appointed as CEO, effective January 14, 2027; Arun Menawat to transition to Executive Chairman; Matthew Sobczyk becomes permanent CFO; Jason Mills joins Board TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).
Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chain control, therapeutic expansion and a target to transition toward earnings growth beginning in 2028.
Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precision Medicine up 30% YoY; Pixclara approval and pipeline advancements offer additional growth catalysts. The ITM acquisition, valued at $1.65 billion with up to $700 million in contingent payments, is expected to deliver $50 million in synergies and meaningful EBITDA from 2027.
Benchmark TLX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Telix Pharmaceuticals Limited (TLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.86 | $3B | -427.78 | 0.84% | -0.89% | -1.42% | — | |
| $68.50 | $17.22B | 19.79 | 6.98% | 35.45% | 45.54% | — | |
| $6.95 | $2.53B | 18.99 | 43.31% | 8.5% | 8.46% | — | |
| $6.21 | $258.6M | 18.41 | 10.37% | 20.98% | — | — | |
| $101.80 | $6.63B | 25.80 | 0.5% | 17.28% | 21.72% | — | |
| $159.13 | $302.46B | 30.21 | 5.97% | 17.82% | 24.32% | 2.53% |
Telix Pharmaceuticals Limited (TLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Telix Pharmaceuticals Limited (TLX) stock FAQ — growth, dividends, profitability & financials explained
Telix Pharmaceuticals Limited (TLX) reported $789.8M in revenue in fiscal year 2025.
Telix Pharmaceuticals Limited (TLX) grew revenue by 0.8% in fiscal year 2025, compared with the prior fiscal year.
No. Telix Pharmaceuticals Limited (TLX) reported a net loss of $7.0M in fiscal year 2025.
Telix Pharmaceuticals Limited (TLX) had a return on equity (ROE) of -1.4% in fiscal year 2025. A negative ROE means the company lost money over the period.
Telix Pharmaceuticals Limited (TLX) had negative free cash flow of $54.2M in fiscal year 2025.